Associated Genetic Biomarkers
Cyclin-dependent kinase inhibitor 2C (CDKN2C, also known as p18) is a gene that encodes a protein that inhibits the activation of CDK 4 and CDK6. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as bone cancer, endometrial cancer, and intestinal cancer.
CDKN2C is altered in 0.71% of all cancers with conventional glioblastoma multiforme, lung adenocarcinoma, glioblastoma, colon adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in CDKN2C are CDKN2C Mutation (0.35%), CDKN2C Loss (0.23%), CDKN2C Amplification (0.12%), CDKN2C Nonsense (0.04%), and CDKN2C Fusion (0.01%) .
CDKN2C status serves as an inclusion eligibility criteria in 6 clinical trials, of which 5 are open and 1 is closed. Of the trials that contain CDKN2C status as an inclusion criterion, 3 are early phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open).
Trials with CDKN2C status in the inclusion eligibility criteria most commonly target glioblastoma, malignant glioma, and multiple myeloma .
The most frequent alterations to serve as inclusion eligibility criteria are CDKN2C Loss and CDKN2C Fusion .
Abemaciclib, dexamethasone, everolimus, ixazomib, and pembrolizumab are the most frequent therapies in trials with CDKN2C as an inclusion criteria .
Significance of CDKN2C in Diseases
Malignant Glioma +
Multiple Myeloma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.